Catalyst Repository | Oyster Point Pharma Inc. Common Stock

Oyster Point Pharma Inc. Common Stock

(NASDAQ:OYST)

Description

Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. The company's lead product candidate is OC-01, a nicotinic acetylcholine receptor agonist that has completed Phase III clinical trial for the treatment of signs and symptoms of dry eye disease. It is also developing OC-01 for neurotrophic keratopathy. Oyster Point Pharma, Inc. was incorporated in 2015 and is headquartered in Princeton, New Jersey.

OYST Overview

None
Sector
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)

Previous Close
$5.5000
Previous Close Volume
36720